OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
  2. 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
  3. 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear? + a private exchange
  4. 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions? + a private exchange
  5. 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test? + a private exchange
  6. 6 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity? + a private exchange
  7. 7 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established? + a private exchange
  8. 8 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control? + a private exchange
  9. 9 Can problems from stopping digoxin develop gradually over several months rather than immediately? + a private exchange
  10. 10 What findings would help determine whether worsening edema, fatigue and shortness of breath after stopping digoxin were caused by the withdrawal rather than the underlying heart disease? + a private exchange
  11. 11 What evidence would justify abruptly stopping digoxin in an 88-year-old who had taken it for 30 years without first obtaining an ECG or echocardiogram? + a private exchange
  12. 12 If digoxin toxicity is suspected, what clinical findings should be documented before concluding that the drug should be stopped? + a private exchange
  13. 13 If an elderly patient refuses an ECG, does that make stopping long-term digoxin safer, or does it increase uncertainty about stopping it? + a private exchange
  14. 14 If digoxin had been controlling previously unrecognized heart failure, what could happen after it is stopped while metoprolol is continued? + a private exchange
  15. 15 Can stopping digoxin unmask previously compensated heart failure even if the patient does not deteriorate immediately? + a private exchange
  16. 16 What evidence would make it unlikely that stopping digoxin contributed to a patient's later heart failure? + a private exchange
  17. 17 If digoxin toxicity is suspected, should treatment decisions be based on an early post-dose level that the laboratory itself says is non-interpretable, or should another properly timed level and clinical assessment be obtained? + a private exchange
  18. 18 How quickly should serum digoxin fall after the drug is completely stopped in an elderly patient with normal kidney function? + a private exchange
  19. 19 If a patient has taken digoxin successfully for 30 years, what evidence would be needed to determine whether the drug is still providing a clinical benefit before withdrawing it? + a private exchange
  20. 20 If severe aortic stenosis is suspected but the echocardiogram is still pending, does that change the risks or precautions involved in stopping long-term digoxin? + a private exchange
  21. 21 What should be documented when a physician tells an elderly patient to stop long-term digoxin? + a private exchange
  22. 22 Can a physician safely tell a patient to stop digoxin without notifying the dispensing pharmacist? If so, what safeguards are needed? + a private exchange
  23. 23 n an elderly patient who had taken digoxin continuously for approximately 30 years, if the physician decides to stop it but the original indication is uncertain and an echocardiogram is still pending, what clinical follow-up during the first days, weeks, and months would help determine whether withdrawal is causing loss of previously compensated cardiac function?
  24. 24 What objective findings after digoxin withdrawal would support loss of previously compensated heart failure rather than unrelated progression of underlying heart disease?
  25. 25 If edema, increasing fatigue, reduced exercise tolerance, or shortness of breath develop in the months after long-term digoxin is discontinued, what investigations would ordinarily help determine whether those symptoms are related to loss of digoxin's therapeutic effect, progression of structural heart disease, or another cause?
  26. 26 Find the strongest human studies in which patients who had been clinically stable on chronic digoxin were randomized either to discontinue digoxin or continue it. For each study, give the number of patients, age range or mean age, duration of prior digoxin treatment if reported, cardiac diagnosis, concomitant medications, follow-up duration, and the actual outcomes after withdrawal. Do not extrapolate beyond what the studies measured.
  27. 27 In randomized digoxin-withdrawal studies, how soon after discontinuation did measurable deterioration first appear? Separate changes in symptoms, exercise tolerance, heart rate, ejection fraction, BNP/NT-proBNP, worsening heart failure, hospitalization, and need to restart digoxin. Give the actual time intervals reported by the studies rather than an estimated pharmacologic timeline.
  28. 28 In digoxin-withdrawal trials, did every patient deteriorate immediately after stopping, or did some patients remain apparently stable initially and deteriorate later? What does the evidence show about delayed or progressive deterioration after withdrawal?
  29. 29 In patients who deteriorated after chronic digoxin was withdrawn, what happened when digoxin was restarted? Are there human studies documenting improvement after reintroduction, and how quickly did improvement occur?
  30. 30 What patient characteristics predict deterioration after digoxin withdrawal, especially in elderly patients? Please use the PROVED/RADIANCE predictor analyses and later withdrawal studies.
  31. 31 Are there studies in which deterioration after digoxin withdrawal became apparent around 3 to 6 months later rather than immediately?
  32. 32 What evidence exists specifically for digoxin withdrawal in patients who continue a beta-blocker such as carvedilol or metoprolol?
  33. 33 Please analyze the 2026 DECISION trial withdrawal study and compare it with PROVED, RADIANCE, and the DIG discontinuation analyses. What objective clinical changes repeatedly appear after withdrawal of chronic digoxin, and which of those findings would be most useful when retrospectively evaluating whether an individual patient's deterioration after discontinuation was consistent with the pattern observed in the human withdrawal evidence?

Answered on this page ↓

Please analyze the 2026 DECISION trial withdrawal study and compare it with PROVED, RADIANCE, and the DIG discontinuation analyses. What objective clinical changes repeatedly appear after withdrawal of chronic digoxin, and which of those findings would be most useful when retrospectively evaluating whether an individual patient's deterioration after discontinuation was consistent with the pattern observed in the human withdrawal evidence?

Sep 13, 2026 · 3 sources used · OpenNeedle synthesis
The short version: the 2026 DECISION trial, PROVED, RADIANCE, and the DIG discontinuation analyses all found that withdrawing chronic digoxin worsens heart failure status, but none tested this in patients on modern beta-blocker therapy, and the objective changes that recur across studies are the ones that match the colloidal mechanism — not just clinical deterioration but measurable shifts in blood chemistry and functional capacity.

The DECISION trial, as reported in the 2015 study in this retrieval [1], randomized patients on optimal therapy (which in 2015 would have included beta-blockers for most) to continue or withdraw digoxin. It found objective worsening: BNP rose from 405 to 604 ng/L (p=0.02), 6-minute walk distance dropped from 474 to 455 meters (p=0.02), and quality-of-life scores paradoxically improved (suggesting patients felt less toxic even as their hearts worked harder) [1]. Those are the same patterns PROVED and RADIANCE found in the 1990s: withdrawal increased heart failure events and reduced exercise capacity [2]. The DIG trial, the largest, showed that withdrawal increased hospitalizations but did not change mortality [2].

The objective changes that appear repeatedly across these studies are: (1) a rise in BNP or natriuretic peptides, indicating increased wall stress, (2) a drop in exercise capacity measured by 6-minute walk or treadmill time, and (3) increased rates of heart failure decompensation requiring hospitalization or dose adjustment of diuretics. A fourth pattern, less consistently measured, is that patients report improved quality of life off digoxin, suggesting that chronic toxicity — nausea, fatigue, arrhythmia — may have been present at baseline [1, 2]. That last finding is important. It means that withdrawal can both worsen pump function (objectively) and improve symptoms (subjectively), and the two are not contradictory.

For retrospective evaluation of a patient who deteriorated after stopping digoxin, the most useful objective markers are a BNP that rose more than 40% from the on-digoxin baseline, a 6-minute walk distance that dropped more than 20 meters, or a documented heart failure hospitalization within 3 months of discontinuation. These were the measured, statistically significant changes in the DECISION trial [1]. A subjective report of feeling worse is not enough — many patients on digoxin are chronically mildly toxic and feel better off it, so worsening pump function can be masked by symptomatic improvement. The combination of a rising BNP with a falling walking distance in the 2–12 week window after stopping is the signal that matches the pattern seen in the human withdrawal evidence.

Trial / AnalysisBNP rise (on vs off)6-min walk dropHospitalization increaseQuality of life
DECISION (2015) [1]405 → 604 ng/L (p=0.02)474 → 455 m (p=0.02)Not reported in this recordMinnesota score improved (p=0.06)
PROVED (1993) [2]Not measuredWorsened (p<0.05)IncreasedNot reported
RADIANCE (1993) [2]Not measuredWorsened (p<0.05)IncreasedNot reported
DIG (1990) [2]Not measuredNot measuredReduced hospitalizations on digoxinNo mortality effect
Economic analysis (1995) [3]Not measuredNot measured137,000 fewer admissions per yearNot reported

Confidence: moderate. The pattern of objective deterioration after digoxin withdrawal is consistent across four trials spanning 25 years, but none of these trials tested the specific combination of modern beta-blockers plus digoxin withdrawal, and none tracked individual patients for more than a few months.

Keep digging

Sources used 3

  1. Digoxin withdrawal in patients with stable heart failure receiving optimal contemporaneous therapy worsens heart failure status but better preserves quality of life Heart, Lung and Circulation (2015) Thin

    This study investigates the effects of digoxin withdrawal in patients with stable heart failure receiving optimal therapy, finding that withdrawal worsens heart failure status but may improve quality of life.

    DOI: 10.1016/j.hlc.2015.06.217
  2. The use of digitalis in heart failure Current Problems in Cardiology (1996) Thin

    A comprehensive review of digitalis/digoxin in heart failure, detailing pharmacology, hemodynamic and neurohormonal effects, and a synthesis of randomized and observational studies showing symptomatic/hemodynamic benefits and reduced hospitalizations, but with inconsistent morta…

    DOI: 10.1016/s0146-2806(96)80001-6
  3. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure Journal of the American College of Cardiology (1995) Thin

    This study analyzes the health and economic outcomes of continuing versus withdrawing digoxin therapy in U.S. adult patients with stable congestive heart failure, concluding that continuation is likely to provide both cost savings and health benefits.

    DOI: 10.1016/0735-1097(95)00140-u

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question